Document is current

Article History

Received: 19 April 2024

Accepted: 1 October 2024

First Online: 21 November 2024

Declarations

:

: E.S. received personal fees from AbbVie, Amgen, Arena Pharmaceuticals, Benevolent AI Bio Limited “BAI”, BiomX Ltd, Bluefin Biomedicine, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen LLC (CA), Coronado, Dermira, Eli Lilly, Evidera, Excerpta Medica, Forte Bio RX, Incyte, Janssen, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Medscape LLC, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and SPARC India; and grants (or principal investigator role) from AbbVie, Amgen, Eli Lilly, Incyte, Kyowa Hakko Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, and Tioga and Vanda Pharmaceuticals. D.M.P. was a consultant for Abbott Laboratories, Amgen, Asana BioSciences, LLC, Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Celgene Corporation, Dermira, Dermavant Sciences, DUSA Pharmaceuticals, Inc, Eli Lilly and Company, LEO Pharma, US, Merck and Co, Inc, Novartis Pharmaceuticals Corp, Novo Nordisk A/S, Ortho Dermatologics, Peplin, Inc, Pfizer, Inc, Photocure ASA, Promius Pharma, LLC, Regeneron Pharmaceuticals, Inc, Sanofi, Stiefel (a GSK company), TDM SurgiTech, Inc, TheraVida, Inc, and Valeant Pharmaceuticals International. J.D., M.B., and S.F. received research funding for the current study from Research Triangle Institute Health Solutions. Z.W. is an employee and shareholder of Regeneron Pharmaceuticals, Inc. C.C.C. is an employee and may hold stock and/or stock options in Sanofi.

: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki of 1964 (including its later amendments) and the International Council for Harmonization Good Clinical Practice guideline. This study received Research Triangle Institute institutional review board approval.